Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Septerna, Inc. (SEPN) Financial Statements

Septerna, Inc. (SEPN) reported trailing twelve-month revenue of $98.9M (down 23.4% year on year) and net income of -$24.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $105.1M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

SEPNSepterna, Inc.Follow SEPN — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
1.9B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
9 Nov, in 16 days

Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.

LineFY2024
Dec 24
FY2025
Dec 25
TTM
Jun 26
Trend
Revenue1.146.098.9
Research & development65.397.6120.8
Operating income-80.8-68.3-43.5
Pre-tax income-72.3-48.9-22.9
Income tax-0.50.01.3
Net income-71.8-48.9-24.2
Diluted EPS ($)-7.26-1.10-0.54
Diluted shares (mn)9.944.3—

USD millions · SEC XBRL

Septerna, Inc. — questions

What is Septerna, Inc.'s revenue?
$98.9M over the twelve months to 2026-06-30, down 23.4% year on year, from its 10-Q and 10-K filings.
What is Septerna, Inc.'s net income?
-$24.2M over the twelve months to 2026-06-30.
What is Septerna, Inc.'s free cash flow?
$105.1M over the twelve months to 2026-06-30.
What are Septerna, Inc.'s diluted earnings per share?
$-0.54 over the twelve months to 2026-06-30.

Every figure on this page comes from Septerna, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.